PD-L1 expression and other potential biomarkers, including tumor-infiltrating lymphocyte (TIL), microsatellite instability (MSI), tumor mutation burden (TMB), and Epstein–Barr virus (EBV), are predictive markers for ICI treatment outcomes in gastric cancer [15–17]. This evidence concerns the gene CD274 and neoplasm.